Provided by Tiger Trade Technology Pte. Ltd.

Health in Tech

0.9600
-0.0200-2.04%
Post-market: 0.96000.00000.00%19:41 EDT
Volume:46.42K
Turnover:45.13K
Market Cap:62.91M
PE:-14.70
High:0.9899
Open:0.9800
Low:0.9600
Close:0.9800
52wk High:4.02
52wk Low:0.8501
Shares:65.53M
Float Shares:20.30M
Volume Ratio:1.31
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0653
EPS(LYR):0.0200
ROE:-21.91%
ROA:-12.72%
PB:3.22
PE(LYR):48.00

Loading ...

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

GlobeNewswire
·
Yesterday

Health In Tech price target lowered to $3 from $4 at Maxim

TIPRANKS
·
Aug 16

Maxim Group Sticks to Their Buy Rating for Health In Tech, Inc. Class A (HIT)

TIPRANKS
·
Aug 14

Health in Tech Q2 FY26 Net Loss Widens to $2.5 Million; Revenue Falls to $8.1 Million

Reuters
·
Aug 14

Health In Tech Q2 EPS $(0.04) Misses $(0.03) Estimate, Sales $8.057M Beat $7.547M Estimate

Benzinga Earnings
·
Aug 14

Health in Tech - Reaffirms Full-Year 2026 Revenue Guidance of $45 Mln to $50 Mln

THOMSON REUTERS
·
Aug 14

Press Release: Health in Tech Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 14

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

GlobeNewswire
·
Aug 14

Health in Tech Inc Expected to Post a Loss of 2 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Health in Tech to Report Q2 2026 Results, Host Earnings Call

Reuters
·
Aug 04

Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation

GlobeNewswire
·
Aug 03

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

GlobeNewswire
·
Jul 21

Health in Tech Inc Expected to Post a Loss of 2 Cents a Share - Earnings Preview

Reuters
·
Jul 18

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

GlobeNewswire
·
Jul 13

AJJ Medtech sets governance framework for HIT-1 humanoid eldercare platform

TIPRANKS
·
Jul 13

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire
·
Jul 01

Health In Tech Added to Russell Microcap Index

MT Newswires Live
·
Jun 29

Health In Tech added as member of Russell Microcap Index

TIPRANKS
·
Jun 29

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

GlobeNewswire
·
Jun 24

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

GlobeNewswire
·
Jun 18